Repare Therapeutics Inc. reported positive data from its MYTHIC Phase 1 gynecologic expansion clinical trial evaluating the combination of lunresertib and camonsertib (Lunre+Camo). The trial focused on patients with endometrial cancer and platinum-resistant ovarian cancer (PROC) harboring lunre-sensitizing biomarkers.
In evaluable endometrial cancer patients (N=27), the combination achieved a 25.9% overall response rate (ORR), while in PROC patients (N=24), the ORR was 37.5%. Nearly half of the gynecologic cancer patients maintained progression-free survival at 24 weeks, which compares favorably to current standard of care.
The company plans to initiate a registrational Phase 3 trial of Lunre+Camo in endometrial cancer in the second half of 2025, following positive feedback from the U.S. Food and Drug Administration (FDA) and the European Medicines Agency. Additionally, a small contribution of components trial in up to 40 patients with endometrial cancer is expected to begin in the first quarter of 2025.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.